
    
      The trial is an open label extension study. Eligible patients from the RPC01-201, RPC01-301,
      and RPC01-1001 trials diagnosed with relapsing Multiple Sclerosis (RMS) will be enrolled to
      receive study drug until the end of the trial or until the Sponsor discontinues the
      development program.
    
  